ES2564092T3 - Exotoxinas de pseudomonas mutadas con antigenicidad reducida - Google Patents
Exotoxinas de pseudomonas mutadas con antigenicidad reducida Download PDFInfo
- Publication number
- ES2564092T3 ES2564092T3 ES10179539.1T ES10179539T ES2564092T3 ES 2564092 T3 ES2564092 T3 ES 2564092T3 ES 10179539 T ES10179539 T ES 10179539T ES 2564092 T3 ES2564092 T3 ES 2564092T3
- Authority
- ES
- Spain
- Prior art keywords
- essay
- exotoxins
- pes
- mutated
- reduced antigenicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Exotoxina A de Pseudomonas ("PE") aislada, en la que dicha PE tiene una sustitución de alanina, glicina, serina o glutamina en lugar del resto aminoacídico E548, en la que el resto aminoacídico E548 se define en referencia a la secuencia de aminoácidos de la PE nativa (SEQ ID NO:1).
Description
los promotores T7, trp, lac o λ, un sitio de unión a ribosomas y preferentemente una señal de terminación de la transcripción. Para células eucariotas, las secuencias de control pueden incluir un promotor y preferentemente un potenciador derivado de genes de inmunoglobulinas, SV40, citomegalovirus y una señal de poliadenilación y pueden incluir secuencias donadoras y aceptoras de corte y empalme. Las casetes de la invención pueden transferirse a la
5 célula hospedadora elegida por procedimientos bien conocidos como la transformación por cloruro de calcio o la electroporación para E. coli y el tratamiento con fosfato de calcio, la electroporación o la lipofección para células de mamíferos. Las células transformadas con las casetes pueden seleccionarse por la resistencia a antibióticos conferida por genes contenidos en las casetes, como los genes amp, gpt, neo e hyg.
10 [00127] El experto reconocerá que es posible hacer modificaciones en un ácido nucleico que codifica un polipéptido de la presente invención (es decir, PE o un inmunoconjugado formado a partir de una PE de la invención) sin disminuir su actividad biológica. Algunas modificaciones pueden hacerse para facilitar la clonación, la expresión, o la incorporación de la molécula de reconocimiento en una proteína de fusión. Tales modificaciones son bien conocidas para los expertos en la técnica e incluyen, por ejemplo, codones de terminación, una metionina añadida al extremo
15 amino para proporcionar un sitio de iniciación, aminoácidos adicionales colocados en cualquiera de los extremos para crear sitios de restricción localizados convenientemente o aminoácidos adicionales (como poli-His) para facilitar las etapas de purificación.
[00128] Además de mediante procedimientos recombinantes, los inmunoconjugados y las PE de la presente
20 invención pueden construirse también en parte o en su totalidad mediante síntesis peptídica estándar. La síntesis en fase sólida de los polipéptidos de la presente invención de menos de 50 aminoácidos de longitud puede realizarse mediante la unión del aminoácido C-terminal de la secuencia a un soporte insoluble, seguida de la adición secuencial de los aminoácidos restantes de la secuencia. Las técnicas para la síntesis en fase sólida se describen en Barany y Merrifield, THE PEPTIDES: ANALYSIS, SYNTHESIS, BIOLOGY. Vol. 2: SPECIAL METHODS IN
25 PEPTIDE SYNTHESIS, parte A, págs. 3-284; Merrifield y col., J. Am. Chem. Soc. 85: 2149-2156 (1963) y Stewart y col., SOLID PHASE PEPTIDE SYNTHESIS, 2a edición, Pierce Chem. Co., Rockford, IL, EE. UU. (1984). Es posible sintetizar proteínas de mayor longitud por condensación de los extremos amino y carboxilo de fragmentos más cortos. Los procedimientos para formar enlaces peptídicos por activación de un extremo carboxilo terminal (p. ej., mediante el agente de acoplamiento N, N’-diciclohexilcarbodiimida) son conocidos para los expertos.
30
[00129] Una vez expresados, los inmunoconjugados y PE recombinantes de la presente invención pueden purificarse según procedimientos estándar de la técnica, como precipitación con sulfato de amonio, columnas de
35 afinidad, cromatografía en columna y similares (véase generalmente R. Scopes, PROTEIN PURIFICATION, Springer-Verlag, NY, EE. UU. (1982). Se prefieren composiciones sustancialmente puras con una homogeneidad de al menos aproximadamente el 90-95% y una homogeneidad del 98 al 99% es la más preferida para usos farmacéuticos. Una vez purificados, parcialmente o hasta homogeneidad, según se desee, si han de usarse terapéuticamente, los polipéptidos no deberán contener sustancialmente ninguna endotoxina.
40 [00130] Los procedimientos para la expresión de anticuerpos de una sola cadena y/o su plegamiento para obtener una forma activa apropiada, incluidos los anticuerpos de una sola cadena de bacterias como E. coli , han sido descritos y son bien conocidos y aplicables a los anticuerpos de esta invención. Véase Buchner y col., Anal. Biochem. 205: 263-270 (1992); Pluckthun, Biotechniology 9: 545 (1991); Huse y col., Science 246: 1275 (1989) y
45 Ward y col., Nature 341: 544 (1989), todos ellos incorporados por referencia en este documento.
[00131] Frecuentemente, las proteínas heterólogas funcionales de E. coli o de otras bacterias se aíslan de cuerpos de inclusión y requieren la solubilización mediante desnaturalizantes fuertes y un subsiguiente plegamiento. Durante la etapa de solubilización, tal como es bien conocido en la técnica, debe haber presente un agente reductor para
50 separar los puentes disulfuro. Un tampón de ejemplo con un agente reductor es: Tris 0,1 M pH 8, guanidina 6 M, EDTA 2 mM, DTE (ditioeritritol) 0,3 M. La reoxidación de los puentes disulfuro puede tener lugar en presencia de reactivos tiólicos de bajo peso molecular en forma reducida y oxidada, tal como se describe en la publicación de Saxena y col., Biochemistry 9: 5015-5021 (1970), incorporada por referencia en este documento, y especialmente tal como describen Buchner y col., cita anterior.
55 [00132] Típicamente la renaturalización se consigue por dilución (p. ej., 100 veces) de la proteína desnaturalizada y reducida en el tampón de plegamiento. Un tampón de ejemplo es Tris 0,1 M pH 8,0, L-arginina 0,5 M, glutatión oxidado 8 mM y EDTA 2 mM.
20
Fusión Inmunización Refuerzo Ratón Título Procedimiento Número de final de cribado clones finales (c) 14 M1-ip x 4 D553E-ip C3H Hej 3 x 104 ICC con 0 CD30 15 M1-ipx3+ III-ip A/J 3x105 ICCcon30 3 D553E x 2 16 M1-ip x 3 + D553E-ip A/J 3 x 105 ICC con 13 D553E x 2 CD30
(c) Los clones se seleccionan por su alta afinidad relativa en ICC-ELISA con M40-3 como estándar. M1: M1(dsFv)-PE38, D553E: mutante de LMB-2 con D553E, R276G: mutante de M1(scFv)PE38 con R276G, III: dominio III
Tabla 2. Lista de MAb estudiados
- Nombre
- Epítopo Isotipo Título (log µl/µg) Afinidad (nM)
- IP43
- 1a γ/I 2,6 0,10
- IP62
- 1a γ/I 2,5 0,2
- IP57
- 1a γ/I 1,9 0,00039
- IP11
- 1b γ/I 2,6 6*
- IP39
- 1b γ/I 2,8 0,93*
- IP47
- 1b γ/I 2,8 0,47*
- IP70
- 1b γ/I 2,5 58*
- IP48
- 1b γ/I 2,7 3,3*
- IP1
- 1b γ/I 2,6 5,80
- IP35
- 1b γ/I 2,8 3,70
- IP36
- 1b γ/I 2,6 3,60
- IP42
- 1b γ/I 2,5 43
- IP34
- 2a γ/I 2,7 0,11*
- IP29
- 2b γ/I 2,8 20
- IP63
- 2b γ/I 2,7 5
- IP2
- 2b γ/I 2,7 0,30
- IP15
- 2c γ/I 2,6 5,3
- IP22
- 2c γ/I 2,6 3,4*
- IP51
- 2c γ/I 2,2 3,10
- IP76
- 2c γ/I 3,0 0,19
- IP83
- 2c γ/I 2,5 0,43
- IP9
- 3a γ/I 2,4 4,80
- IP18
- 3a γ/I 2,5 0,09*
- IP16
- 3a γ/I 2,5 0,24*
- IP32
- 3a γ/I 2,7 33
- IP44
- 3b γ/I 2,5 0,14
- IP45
- 3b γ/I 2,9 0,47
- IP58
- 3b γ/I 2,4 0,24
- IP7
- 4a γ/I 2,7 0,04
- IP10
- 4a γ/I 2,1 0,04
- IP31
- 4a γ/I 2,9 0,27*
- IP37
- 4a γ/I 2,7 1,40
- IP49
- 4a γ/I 1,7 2,60
- IP3
- 4a γ/I 2,6 0,00038
- IP27
- 4a γ/I 2,7 16*
- IP72
- 4a γ/I 2,8 4,4*
- IP14
- 4b γ/I 2,6 81
- IP82
- 4b γ/I 2,7 11*
- IP86
- 4b γ/I 2,9 0,41*
- IP13
- 5 γ/I 2,6 1,2
- IP20
- 5 γ/I 2,3 0,1
29
Tabla 4. CI50 de las inmunotoxinas preparadas por mutación de la PE en restos que afectan a la unión a diferentes epítopos
- Ensay o n° 14
- 0,7
- Ensay o n° 13
- 0,44
- Ensay o n° 12
- 1,8
- Ensay o n° 11
- 1,0
- Ensay o n° 10
- 0,9 0,7 0,7
- Ensay o n° 9
- 0,7 0,55 30 >100 0,4
- Ensay o n° 8
- 2,0 1,9(?) 4,4 5,0/6,2
- Ensay o n° 7
- 0,2 0,45
- Ensay o n° 6
- 4 6 5 10
- Ensay o n° 5
- 3,3 3,7 4,2 6,5
- Ensay o n° 4
- 3,4 4,5
- Ensay o n° 3
- 1,0 1,0
- Ensay o n° 2
- 1,0 2,0 1,1 3,0
- Ensay o n° 1
- 1,2ng/ml 3,0 0,72 0,72 1,5 2,1
- N° de MAb bloqueados al mutar este resto
- 8 8 8 3 3 3 3 3/3 8 3 3 3
- N° de MAb en este grupo epitópico
- 37 8 3 3 3 3/3 8 3 3 3
- Epítopo
- 1 1 1 2c 5 2c 1/5/7 7 5/7 5/1 5/2/7 1 5 2 7
- IT con los res tos designados mutados en la secuencia de la PE
- InmunotoxinaHA22(control) N314A* N314S Q332A R467A R490A R538A* Q332A R490AK590A/K606A/613del* K590A R490AK590A* Q332AR490A* K606A* R490A R538AK590A* Q332S R490S* R538S* K590S
31 32
(continuación) */ La mutación redujo la citotoxicidad en más del 50%
- Ensay o n° 14
- 0,9 0,8
- Ensay o n° 13
- 0,7
- Ensay o n° 12
- 1,0 0,8
- Ensay o n° 11
- 0,75 0,6
- Ensay o n° 10
- 0,8
- Ensay o n° 9
- Ensay o n° 8
- Ensay o n° 7
- Ensay o n° 6
- Ensay o n° 5
- Ensay o n° 4
- Ensay o n° 3
- Ensay o n° 2
- Ensay o n° 1
- N° de MAb bloqueados al mutar este resto
- 17 22 5
- N° de MAb en este grupo epitópico
- (5) 6
- Epítopo
- 1/2c/5/7 3/1/2c/5/7 3/1/4a/2c/5/7 3/1/4a/2c/5/6/7 3/1/4a/2c/5/6/6/7
- IT con los res tos designados mutados en la secuencia de la PE
- Q332S R467AR490A K590S R313A Q332SR467A R490AK590S R313A Q332SR432G R467AR490A K590S R313A Q332SR432G R467AR490A R513AK590S R313A Q332SR432G R467AR490A R513AE548S K590S
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70379805P | 2005-07-29 | 2005-07-29 | |
US703798P | 2005-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2564092T3 true ES2564092T3 (es) | 2016-03-17 |
Family
ID=37709138
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15191388T Active ES2702650T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES10179539.1T Active ES2564092T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES15191391.0T Active ES2659039T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES06788523T Active ES2372537T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida. |
ES15191395.1T Active ES2660026T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES10179520T Active ES2410783T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15191388T Active ES2702650T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15191391.0T Active ES2659039T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES06788523T Active ES2372537T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida. |
ES15191395.1T Active ES2660026T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
ES10179520T Active ES2410783T3 (es) | 2005-07-29 | 2006-07-25 | Exotoxinas de pseudomonas mutadas con antigenicidad reducida |
Country Status (8)
Country | Link |
---|---|
US (1) | US8907060B2 (es) |
EP (6) | EP2332970B1 (es) |
AT (1) | ATE524489T1 (es) |
AU (1) | AU2006275865B2 (es) |
CA (2) | CA2941466C (es) |
ES (6) | ES2702650T3 (es) |
PL (3) | PL3006457T3 (es) |
WO (1) | WO2007016150A2 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7989322B2 (en) | 2007-02-07 | 2011-08-02 | Micron Technology, Inc. | Methods of forming transistors |
WO2008109005A2 (en) * | 2007-03-02 | 2008-09-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
PL2197903T3 (pl) | 2007-09-04 | 2015-03-31 | Us Gov Health & Human Services | Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
RU2012114005A (ru) * | 2009-09-11 | 2013-10-20 | Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез | Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
WO2012015912A1 (en) | 2010-07-30 | 2012-02-02 | Medimmune, Llc | Method for purifying active polypeptides or immunocojugates |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
BR112013006088B1 (pt) | 2010-09-15 | 2022-06-14 | Randall J Mrsny | Construto de entrega isolado, e, composição farmacêutica |
CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
ES2641877T3 (es) | 2011-05-06 | 2017-11-14 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Inmunotoxina recombinante dirigida a mesotelina |
BR112013031262A2 (pt) | 2011-06-09 | 2016-11-22 | Us Health | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". |
US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
AU2012308591B2 (en) | 2011-09-16 | 2017-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic B cell epitopes |
EP2768863B1 (en) | 2011-10-20 | 2017-09-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd22 chimeric antigen receptors |
PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
WO2013181543A1 (en) | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
EP3327037B1 (en) | 2012-08-21 | 2019-10-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
US9416190B2 (en) | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
CA2884431A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
DK2934597T3 (en) | 2012-12-20 | 2019-02-11 | Medimmune Llc | PROCEDURES FOR PREPARING IMMUNCONJUGATES |
AU2014329437B2 (en) * | 2013-10-06 | 2018-10-18 | F. Hoffmann-La Roche Ag | Modified Pseudomonas exotoxin A |
CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
EP3102245B1 (en) | 2014-02-05 | 2021-09-08 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
EP3998077A1 (en) | 2014-05-07 | 2022-05-18 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Epha4に対するヒトモノクローナル抗体及びそれらの使用 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
EP3374396A1 (en) | 2015-11-13 | 2018-09-19 | The United States of America, as represented by the secretary, Department of Health and Human Services | Anti-bcma polypeptides and proteins |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
WO2018119279A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
US11390683B2 (en) | 2017-05-18 | 2022-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
WO2019006280A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE |
WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
EP3762009B1 (en) | 2018-03-08 | 2022-05-11 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
WO2020014482A1 (en) | 2018-07-12 | 2020-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured cd22-specific monoclonal antibody and uses thereof |
AU2019317565A1 (en) | 2018-08-08 | 2021-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CA3119179A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
US20220064324A1 (en) | 2019-01-08 | 2022-03-03 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting mesothelin for treating solid tumors |
EP3883971A1 (en) | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
AU2020299382A1 (en) | 2019-07-02 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind EGFRvIII and their use |
CN114599665A (zh) | 2019-08-16 | 2022-06-07 | 应用分子转运公司 | 组合物、制剂及白细胞介素产生和纯化 |
EP4031250A1 (en) | 2019-10-22 | 2022-07-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
CN116583539A (zh) | 2020-12-22 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
US20240218055A1 (en) | 2021-04-29 | 2024-07-04 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
AU2022291120A1 (en) | 2021-06-09 | 2023-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
WO2023114980A1 (en) | 2021-12-17 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
WO2024104584A1 (en) | 2022-11-17 | 2024-05-23 | University Of Cape Town | Deimmunized pseudomonas exotoxin a |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
DE69131449T2 (de) | 1990-05-11 | 1999-11-25 | The United States Of America, Represented By The Secretary | Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität |
US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
ATE154240T1 (de) | 1992-03-12 | 1997-06-15 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
CA2136724A1 (en) | 1992-06-18 | 1993-12-23 | Ira H. Pastan | Recombinant pseudomonas exotoxin with increased activity |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
EP0871481A1 (en) | 1995-10-27 | 1998-10-21 | Merck & Co., Inc. | Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines |
EP0941334B1 (en) * | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Protease-activatable pseudomonas exotoxin a-like proproteins |
US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
MXPA01011950A (es) * | 1999-05-27 | 2002-05-06 | Gov Health & Human Serv | Inmunoconjugados que tienen alta afinidad de enlace. |
EP1263785A2 (en) | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
AU2001278898A1 (en) * | 2000-07-10 | 2002-01-21 | Xencor | Method for disigning protein libraries with altered immunogenicity |
ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
EP1448584B1 (en) * | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
EP1448237A1 (en) | 2001-11-09 | 2004-08-25 | Neopharm, Inc. | Selective treatment of il-13 expressing tumors |
US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
JP2010534061A (ja) * | 2007-07-20 | 2010-11-04 | ザ ジェネラル ホスピタル コーポレイション | 組換えコレラ菌外毒素 |
PL2197903T3 (pl) * | 2007-09-04 | 2015-03-31 | Us Gov Health & Human Services | Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną |
AU2010230063B2 (en) * | 2009-03-24 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
RU2012114005A (ru) * | 2009-09-11 | 2013-10-20 | Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез | Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью |
CA2800488A1 (en) * | 2010-05-26 | 2011-12-01 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-cd133 antibodies and uses thereof |
BR112013031262A2 (pt) * | 2011-06-09 | 2016-11-22 | Us Health | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". |
-
2006
- 2006-07-25 ES ES15191388T patent/ES2702650T3/es active Active
- 2006-07-25 WO PCT/US2006/028986 patent/WO2007016150A2/en active Application Filing
- 2006-07-25 ES ES10179539.1T patent/ES2564092T3/es active Active
- 2006-07-25 ES ES15191391.0T patent/ES2659039T3/es active Active
- 2006-07-25 PL PL15191391T patent/PL3006457T3/pl unknown
- 2006-07-25 PL PL15191388T patent/PL3006456T3/pl unknown
- 2006-07-25 EP EP10179539.1A patent/EP2332970B1/en active Active
- 2006-07-25 EP EP15191388.6A patent/EP3006456B1/en active Active
- 2006-07-25 PL PL15191395T patent/PL3006458T3/pl unknown
- 2006-07-25 CA CA2941466A patent/CA2941466C/en active Active
- 2006-07-25 ES ES06788523T patent/ES2372537T3/es active Active
- 2006-07-25 AT AT06788523T patent/ATE524489T1/de not_active IP Right Cessation
- 2006-07-25 EP EP15191391.0A patent/EP3006457B1/en active Active
- 2006-07-25 EP EP06788523A patent/EP1910407B1/en active Active
- 2006-07-25 AU AU2006275865A patent/AU2006275865B2/en active Active
- 2006-07-25 US US11/997,202 patent/US8907060B2/en active Active
- 2006-07-25 CA CA2616987A patent/CA2616987C/en active Active
- 2006-07-25 ES ES15191395.1T patent/ES2660026T3/es active Active
- 2006-07-25 EP EP15191395.1A patent/EP3006458B1/en active Active
- 2006-07-25 EP EP10179520.1A patent/EP2311854B1/en active Active
- 2006-07-25 ES ES10179520T patent/ES2410783T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP3006458B1 (en) | 2017-11-22 |
PL3006457T3 (pl) | 2018-05-30 |
PL3006456T3 (pl) | 2019-05-31 |
EP3006456B1 (en) | 2018-09-19 |
EP2332970A2 (en) | 2011-06-15 |
EP2311854A1 (en) | 2011-04-20 |
ES2372537T3 (es) | 2012-01-23 |
EP1910407B1 (en) | 2011-09-14 |
ATE524489T1 (de) | 2011-09-15 |
ES2702650T3 (es) | 2019-03-04 |
EP1910407A2 (en) | 2008-04-16 |
EP3006457B1 (en) | 2017-11-22 |
PL3006458T3 (pl) | 2018-05-30 |
ES2660026T3 (es) | 2018-03-20 |
EP2332970A3 (en) | 2011-09-14 |
CA2941466A1 (en) | 2007-02-08 |
EP3006457A1 (en) | 2016-04-13 |
EP3006456A1 (en) | 2016-04-13 |
CA2941466C (en) | 2019-12-03 |
CA2616987C (en) | 2016-10-11 |
ES2659039T3 (es) | 2018-03-13 |
EP2332970B1 (en) | 2015-12-23 |
EP2311854B1 (en) | 2013-04-17 |
WO2007016150A3 (en) | 2007-08-09 |
AU2006275865A1 (en) | 2007-02-08 |
EP3006458A1 (en) | 2016-04-13 |
US20090142341A1 (en) | 2009-06-04 |
CA2616987A1 (en) | 2007-02-08 |
AU2006275865B2 (en) | 2012-06-28 |
WO2007016150A2 (en) | 2007-02-08 |
ES2410783T3 (es) | 2013-07-03 |
US8907060B2 (en) | 2014-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2564092T3 (es) | Exotoxinas de pseudomonas mutadas con antigenicidad reducida | |
US6147203A (en) | Recombinant disulfide-stabilized polypeptide fragments having binding specificity | |
ES2362386T3 (es) | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro. | |
Chaudhary et al. | A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. | |
Whitlow et al. | Single-chain Fv proteins and their fusion proteins | |
Reiter et al. | Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv | |
CN105477641B (zh) | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 | |
ES2638340T3 (es) | Anticuerpo monoclonal contra interleucina-31 de perro | |
US7906624B2 (en) | Binding peptidomimetics and uses of the same | |
CN108136043B (zh) | 蛋白质缀合物 | |
ES2870802T3 (es) | Métodos de replegado de proteínas a elevado pH | |
KR20030081315A (ko) | 화학적으로 합성한 폴리펩티드의 폴딩 방법 | |
US11345745B2 (en) | Peptide-hinge-free flexible antibody-like molecule | |
Hoffmann et al. | PK modulation of haptenylated peptides via non-covalent antibody complexation | |
ES2813501T3 (es) | Métodos de replegado de proteínas basados en filtración de flujo tangencial | |
Brinkmann et al. | Stabilization of a recombinant Fv fragment bybase-loop interconnection and VH-VL permutation | |
Kipriyanov et al. | Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines | |
Singh | Surface plasmon resonance (SPR) based binding studies of refolded single chain antibody fragments | |
Katayama et al. | Application of 2, 2′‐dipyridyl disulfide‐mediated thiazolidine ring‐opening reaction to glycoprotein synthesis: Total chemical synthesis of evasin‐3 | |
CN116867800A (zh) | 双特异性或多特异性抗体 | |
Li et al. | Utilization of selenocysteine for site-specific antibody conjugation | |
JP2020511519A (ja) | 操作された安定なch2ポリペプチド | |
Patil et al. | Expression, refolding, purification and characterization of single chain antibody fragment produced in Escherichia coli | |
WO2022080385A1 (ja) | ペプチド、およびペプチドを用いる抗体の修飾 | |
Whitlow | Protein Engineering Strategies |